Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

701.85 -6.40 (-0.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,889,991
Open 710.20
Bid (Size) 706.00 (2)
Ask (Size) 725.00 (5)
Prev. Close 708.25
Today's Range 700.83 - 717.61
52wk Range 693.00 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-22.45%
-22.45%
1 Month
-5.58%
-5.58%
3 Month
-38.70%
-38.70%
6 Month
-33.36%
-33.36%
1 Year
-16.63%
-16.63%

More News

Read More
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Via Benzinga
Exposures Product Safety
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Via Benzinga
Topics Economy
Exposures Interest Rates
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Check Out What Whales Are Doing With REGN
Via Benzinga
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Via Benzinga
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Via Investor's Business Daily
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Via Benzinga
It’s Been A Tough Month For Healthcare Stocks
Via Talk Markets
Topics ETFs Stocks / Equities
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Not-So-Big Pharma
Via Talk Markets
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Top Growth Stocks to Buy on the Dip
Via The Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Via Benzinga
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.